1,2-dihydroquinobenzoxa(or thia)zepine derivatives

ABSTRACT

WHEREIN Z is O, or N-OH, A is O, S, SO or SO2 and X, Y, n and n&#39;&#39; are as defined hereinafter. These compounds are useful as antifungal agents and antibacterial agents. D R A W I N G 1,2-Dihydroquinobenzoxa(or thia)zepine derivatives are provided having the structures

United States Patent Yale et al.

[451 July 11, 1972 [54] l ,2-DIHYDROQUINOBENZOXA(OR THIA)ZEPINE DERIVATIVES [72] Inventors: Harry Louis Yale; Ramesh Petigara, both of New Brunswick, NJ.

[73] Assignee: E. R. Squibb & Sons, Inc., New York,

[22] Filed: Oct. 27, 1970 [21] Appl.No.: 84,533

[56] References Cited UNITED STATES PATENTS 2,919,271 12/1959 Craig et al ..260/283 SY Primary Examiner-Henry B. Jiles Assistant Examiner-Robert T. Bond AuorneyLawrence S. Levinson, Merle J. Smith, Donald J.

Perrella and Burton Rodney [5 7] ABSTRACT l,2-Dihydroquinobenzoxa(or thia)zepine derivatives are provided having the structures wherein Z is O, or NOH, A is O, S, S0 or S0 and X, Y, n and n are as defined hereinafter. These compounds are useful as antifungal agents and antibacterial agents.

14 Claims, No Drawings A winl V ll wherein X and Y are the same or different and can be halogen, trifluoromethyl, lower alkyl, lower alkylmercapto, lower alkyloxy, cyano, or di-lower alkysulfamoyl, A is O, S, S0 or S0 2 is O or=N0H, n is O, l or 2 and n is O, l or 2.

The term lower alkyl" as employed herein includes both straight and branched chain radicals of up to and including eight carbon atoms, for instance, methyl, ethyl, propyl, isopropyl, butyl, s-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl and the like. The lower alkyl group can include substituents such as aryl.

The term halogen" includes F, Cl, Br or I.

The lower alkylmercapto groups contain up to eight carbon atoms and include methylmercapto, ethylmercapto, propylmercapto and mercapto radicals containing any of the lower alkyl groups mentioned hereinbefore.

The terms lower alkyloxy" andlower alkoxy" are interchangeable and refer to groups containing up to eight carbon atoms and which include any of the lower alkyl groups mentioned hereinbefore attached to a oxygen atom.

In the above Formulas I and I], each of the carbocyclic aromatic rings can include 0, l or 2 substituents, other than hydrogen. The nature and position of the substituents in the starting materials will determine which isomer, Type I and/or Type II, is obtained.

As will be seen hereinafter, the compounds of the invention are prepared from starting materials of the structure Where in the starting material III, n is l or 2 and X includes strongly electronegative group like trifluoromethyl, cyano or di-lower alkylsulfamoyl substituent at the 7-position, and n is O or Y is a substituent at a position other than 3 in the starting material, cyclization is directed to the 4-position so that the Type II isomer is subsequently formed. However, where X is an ortho-para orienting group like halogen, especially chlorine, and n is l or 2 and at least one halogen is at the 7- position of starting material III, or Y is lower alkyl, lower alkyloxy, or lower alkylmercapto at any position or a strongly electronegative group at a position other than 3 and n is 0, a mixture of the Type I and Type II isomers is obtained,

Where in the starting material III, n is l or 2 and Y includes a strongly electronegative group like trifluoromethyl, cyano or di-lower alkylsulfamoyl at the 3-position, and n is 0 or X is a substituent at a position other than 7 in the starting material, cyclization is directed to the 6-position so that the Type I isomer is subsequently formed.

Where in the starting material Ill,.;n' is l or 2 and Y includes an ortho-para orienting substituent at the 3-position, and n is 0 or X is a substituent at a position other than in the starting material, cyclization is directed to the 6-position so that the Type I isomer is subsequently formed.

Where n and n are 0, that is where there are no substituents on either aromatic ring, the Type I isomer is obtained, that is IV ACH N/\ fl Where the starting material does not include substituents at the 3 and/or 7 positions, but does include substituents such as lower alkyl, lower alkyloxy, or lower alkylmercapto at the l, 2, 8 and/or 9 positions, the Type I isomer is obtained.

Where the starting material does not include substituents as the 3 and/or 7 positions, but does include strongly electronegative groups at the 1 and/or 9 positions, the Type I isomer is obtained. However, where the starting material unsubstituted at the 3 and/or 7 positions includes a strongly electronegative group at the 2 and/or 8 positions, then a mixture of the Type I and Type II isomers is obtained.

Where X represents a strongly electronegative group like trifluoromethyl, cyano or di-lower alkylsulfamoyl and n is l or 2 at least one X being at the 7-position of the starting material and Y is lower alkyl, lower alkyloxy or lower alkylmercapto at any position or any of the above strongly electronegative groups at a position other than 3 in the starting material and n is 0, l or 2, the Type II isomer is obtained.

Where X is lower alkyl, lower alkyloxy, or lower alkylmercapto and n is 'l or 2 and Y is halogen, trifluoromethyl, cyano or di-lower alkylsulfamoyl, and n is l or 2 at least one Y being at the 3-position of the starting material, the Type I isomer is obtained. In this case, X can be trifluoromethyl or other strongly electronegative group so long as it is not in the 7-position of the starting material as will be seen hereinafter.

Where X is lower alkyl, lower alkyloxy, or lower alkylmercapto, and n is l or 2 and n in (Y),, is O, the Type I isomer is obtained.

Where Y is lower alkyl, lower alkyloxy, or lower alkylmercapto and n is l or 2 and the n in (X), is 0, the Type II isomer is obtained.

Where both X and Y represent lower alkyl, lower alkoxy and/or lower alkylmercapto, at least one of said groups being at the 3 and 7 positions of the starting material, the Type I isomer is obtained.

Preferred are those compounds of Formula I wherein n=0 and n=O and A=O and Z is =0 or =NOI-I; those compounds of Formula I wherein n=O, n=l and Y is Cl at the 1 1- position and Z=0 or =NOI-l and those compounds of Formula II wherein n=l, X is CF at the 4-position, n'=0, A=O and Z is =0 or =N-Ol-I.

Examples of compounds falling within the present invention include, but are not limited to, the following. The symbol A in the formulas below represents -O, S-, SO and SO each formula therefore, in essence, representing four species:

It is to be understood that each of the foregoing ketones can be converted to the corresponding oxime as described hereinafter,

The compounds of the Formulas I and/or II can be prepared by reacting a compound of the structure wherein X, Y, n, n, and A are as defined hereinbefore, with a phosphorus pentahalide, such as phosphorus pentachloride, in a molar ratio of Vzpentahalide of within the range of from about 0.921 to about 1:1, in the absence of oxygen, and in the presence of an inert solvent, such as benzene, toluene, xylene,

pentane, hexane, etc., at a temperature within the range of from about to about 10 C, to form an acyl halide of the structure The compounds of Formulas VII and/or VIII can also be prepared by reacting the starting material.

IX A-C Hz imo H20 0 OH with trifluoroacetic anhydride, polyphosphoric acid or phosphorus pentoxide, in a molar ratio of IX: trifluoroacetic anhydride or polyphosphoric acid, or phosphorus pentoxide of within the range of from about 0.9:1 to about 1:1, in the presence of an inert solvent such as benzene, toluene, xylene, pentane, hexane, etc., at a temperature within the range of from about 10 to about 80 C.

The ketones of Formulas VII and VIII react with hydroxylamine or the hydrohalide salt thereof in the presence of a solvent such as ethanol, methanol, etc. to give the corresponding oximes, that is Compounds of the structure I and II wherein A is S0 or SO, can be prepared as follows:

Compounds of the structures I or II wherein A is S are treated with an oxidizing agent like 11,0, in an alcohol solvent or perbenzoic acid or m-chloroperbenzoic acid in a solvent like chloroform to give sulfoxide of the structures XII or XIII SOCH2 so-oHQ m r\ (X)n G 0:). I (Y).. 5 \N I O- O XII XIII Compounds of Formulas I and [I wherein A is SO can be formed by treating I or II (wherein A is S) with an oxidizing agent like H 0 in formic or acetic acid to give sulfones of the structures XIV and XV, respectively SOg-CHg Z- Z (X)n C (Yahoon (Y). \/\N/ A; XIV XV In addition, sulfoxides of the structures XII or XIII can be treated with hydrogen peroxide in formic or acetic acid to obtain sulfones of the structures XIV or XV.

The starting materials of Formula IX are prepared by several methods. One method comprises reacting compounds having the formula XVI:

with acrylonitrile to vield compounds of formula XVII XVII Y N. JZHzCHaCN wherein n, n, X, Y and A are as defined herein.

This reaction is carried out by employing an excess of the acrylonitrile as the solvent. The temperature utilized in the reaction can be varied from about 0 to about 100 C. with the preferred range being between about 0 and about 75 C. This reaction proceeds expeditiously when a small amount (up to about I percent) of a strong base like sodium hydroxide, sodium methoxide, potassium t-butoxide, or benzyl trimethylammonium hydroxide (Triton B) is used as the catalyst.

Compounds with the nitrile structure XVII are converted to the carboxylic acid of formula IX by heating at reflux temperatures with suflicient aqueous or alcoholic alkali metal hydroxide, e.g., sodium hydroxide or potassium hydroxide in methanol or ethanol.

Another procedure for preparing compounds of formula IX is to treat the compounds of structure XVII with alcoholic hydrogen halide, such as hydrogen chloride in methanol, ethanol, and so forth, at room temperature whereby esters of the structure XVIII are formed.

XVIII AC H2 C (x), G-( h lHzCH1C=O wherein R is lower alkyl By saponifying Compound XVIII with an alkali metal hydroxide, e.g., sodium hydroxide, lithium hydroxide, and so forth, the desired carboxylic acids of structure IX can be recovered.

Examples of compounds of Formula XVI where A is S are set out in US. Pat. Nos. 3,188,321 and 3,188,322.

Examples of compounds of Formula XVll where A is 0 or S can be found in a paper entitled Novel Polycyclic Heterocycles, by Yale et a], J. Med. Chem. 13, 713 (1970).

Examples of compounds of Formula XVI wherein A is S0 or $0 can be found in the above mentioned paper by Yale et al.

Furthermore, compounds of Formula XVI wherein A is SO can be formed by heating a compound of the structure and treating compound XX with m-chloroperbenzoic acid in the presence of chloroform and then treating with ether to form a compound of the structure XXI XXI S OCH2 which can ,be treated with alcohol such as ethanol and base such as aqueous sodium hydroxide to form a compound of the structure XXII S OCH2 F (xx- 5;) n

Compounds of Formula XVI wherein A is SO can be formed by treating compounds of the structure XXIII S CH2 GHQ with an oxidizing agent such as hydrogen peroxide in the presence of formic acid to form a compound of the structure XXIV and treating XXIV with an alcohol such as ethanol and base Examples of starting materials which can be employed in preparing the compounds of the invention include, but are not limited to, the following wherein A can be 0, S, S0 or S0 2. A-C H2 FCQ p1 o N or C HzCHzCOOH 3. ACH2 CH N 0 a /CH l CHgCHzC O OH 5. ACH2 ivso O i 2* on T CH2CH2O 0 OH 7. ACH2 CH2CH2C OOH 8. ACH2 (ill ()lhUll UOOll CHQCHQCOOH 1l. A-CH s- CH 6 C) CH C N HzCHzCOOH 13. ACH2 cm 9 O CH3 N CH oms- O OCH;

N on

OH I

UHQCH COOII I A CH 18. A-CH2 JIHgC HzC OOH 19. ACH:

20. 1 H! CH3 The above starting materials can be employed in the form of their corresponding salts as will be apparent to one skilled in the art.

The new compounds of Formulas l and ll are useful as antimicrobial agents and may be used to combat infections in animal species, such as mice, rats, dogs, guinea pigs and the like, due to organisms such as Trichomonas vaginalis, Trichomanas foetus, Staphyloccocus aureus, Salmonella schottmuelleri, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli, C. albicans or Trichophyton mentagrophyles. For example, a compound or mixture of compounds of Formulas l and ll may be administered orally to an infected animal, e.g., to a mouse, in an amount of about 5 to 25 mg. per kg. per day in 2 to 4 divided doses. These may be conventionally formulated in a tablet, capsule or elixir containing about 10 to 250 mg. per dosage unit, by compounding the active substance or substances with the conventional excipient, vehicle, binder, preservativeflavor, etc., as called for by accepted pharmaceutical practice. They may also be applied topically, e.g., to dermatophytosis in a guinea pig, in a lotion, salve or cream at a concentration of about 0.01 to 3 percent by weight.

They may also be used as surface disinfectants. About 0.01 to l percent by weight of any of these substances may be dispersed on an inert solid or in a liquid such as water and applied as a dust or spray. They may be incorporated also, for example, in a soap or other cleansing agent, e.g., a solid or liquid detergent, detergent composition, for example, in general cleaning, in cleaning dairy barns or equipment or cleaning food handling or processing equipment.

The following examples are illustrative of the invention. All temperatures are on the Centigrade scale.

EXAMPLE 1 l,2-Dihydro-3H,8H-quino[ l,8-a,b][4,l ]benzoxazepin-3-one A. 5,l l-Dihydrodibenz[b,e][ 1,4]oxazepine-5-propionic acid A suspension of 30.4 g of 5,1 l-dihydrodibenz[b,e]-[ l ,4]oxazepine in ml of acrylonitrile is cooled to 05. To this is added with efficient stirring and cooling 0.9 ml of Triton B. The suspension becomes homogeneous and a red solution results with the rise of temperature to 10. The reaction mixture is allowed to come to room temperature and then refluxed for one hour with stirring. The excess of acrylonitrile is removed by known means, water is added, and the solid is filtered. The solid is dried, powdered, and extracted with five 400 ml portions of diethyl ether. The diethyl ether extracts are dried and concentrated to a volume of 250 ml. The white crystalline compound is filtered. The filtrate is again concentrated and the resulting solid is filtered and found to melt at about l38l39.5, and is identified as 5,l dihydrodibenz[b,e][ I,4]oxazepine-5-propionitrile.

The 5,l l-dihydrodibenz[b,e][1,4]oxazepine-5- propionitrile, 5.0 g, is dissolved in 200 ml of methanol and to this 2.24 g of potassium hydroxide dissolved in 20 ml of water is added. The solution is refluxed for 4 hours, and then is concentrated in vacuo. The residue is taken up in 600 ml of H 0, the solution is cooled, and then acidified with 2 percent aqueous HCl. The solid is filtered and dissolved in 600 ml of C H This solution is treated with Darco and then extracted with 600 ml of 2percent aqueous NaOH solution. The extracts are treated with Darco and Hyflo, filtered and the filtrate is acidified with 2 percent aqueous HCl. The solid is filtered and recrystallized from C l-l and found to have a m.p. of about 203-205.

B. 1,2-Dihydro-3H,8H-quino[ l ,8-a,b][4,l ]benzoxazepin-3- one In a 500 ml flask equipped with stirring bar, thermometer, nitrogen inlet, dropping funnel and CaCl guard tube, is suspended 10.8 g of 5,11-dihydrodibenz[b,e][1,4]oxazepine- S-propionic acid in 220 ml of C ll This is cooled to 10, and to it is added a solution of 9.5 g of PCl in 50 ml of benzene in 45 minutes. The reaction mixture is stirred for 1.5 hr. at room temperature. To the resulting solution, 5.5 g of sodium hydrosulfite is added and stirred for minutes. The reaction mixture is filtered and the filtrate is concentrated in vacuo to yield a liquid residue. The residue is triturated with 70 ml of petroleum ether to give a yellow solid, which is filtered. Of the acid chloride residue (9.6 g), 8.6 g are dissolved immediately in 220 ml of benzene.

One gram of the above crude acid chloride is dissolved in 150 ml of boiling petroleum ether, filtered, the filtrate treated with 0.2 g of Darco, refluxed, and filtered again. This is stored overnight in the cold room. Crystallization does not occur. The solution is concentrated to 50 ml and cooled in an acetone-CO bath, when a pale yellow solid separates. This is filtered and dried in vacuo for 15 minutes; it softens at 60 and melts with decomposition at 74-75.

The above solution of 8.6 g of the acid chloride in 220 ml of benzene is placed in a flask equipped with a stirrer, a dropping funnel, and a reflux condenser guarded with a CaCl tube. To this, while stirring, is added dropwise, a solution of 9.0 ml of anhydrous SnCl, is 50 ml of benzene. A viscous red complex forms which turns to violet towards the end of the addition. The reaction mixture is stirred for 1 hour and then 600 ml of other is added. To this, ml of cone. HCl and 150 ml of distilled H O are added and the mixture stirred vigorously for 1 hour. The organic phase is separated, washed, filtered, and solvent removed and the residue is extracted successively with 300, 200, and 200 ml portions of boiling cyclohexane. The combined cyclohexane extracts are concentrated to 75 ml to give 2.9 g of product, mp 1 161 18.

EXAMPLE 2 1,2-Dihydro-3l-l,7H-quino[8,1-c,d][ 1,5]benzoxazepin-3-one, oxime A mixture of 1.25 g of l,2-dihydro-3H,8H-quino[l,8-a,b] [l,5]benzoxazepin-3-one and 0.7 g of NH OI-LHCI is dissolved in 140 ml of hot 70 percent ethanol and refluxed for 6 hours; the reaction mixture is concentrated on the Rinco to 60 ml, when a yellow precipitate forms. After standing overnight in the cold room, a yellow solid forms which is filtered and dried to give 1.35 g of material; mp softens at 155, and melts with decomposition at 170. It is dissolved in 125 ml of refluxing 75 percent ethanol, treated with 0.2 g of Darco and filtered to give 1.2 g of product, mp 190192.

EXAMPLE 3 l l-Chloro- 1 ,2-dihydro-3H,8H-quino[ 1 ,8-a,b][4,1 ]benzoxazepin-3-one A. 3-Chloro-5,l 1-dihydrodibenz[b,e][ 1,4]oxazepine-5- propionic acid A suspension of 24.4 g of 3-chloro-5,l1-dihydrodibenz-[ b,e][ 1,4]oxazepine in 55 ml of acrylonitrile is cooled to 0-5. To this is added with efficient stirring, and cooling, 0.3 ml of Triton B, pausing after each drop of addition. The temperature rises slowly from 3 to 14 and then rapidly to 45 within 5 minutes with the formation of red colored clear solution. The mixture is cooled to 5-l0, stirred for 5 minutes, allowed to come to room temperature and then slowly heated to reflux temperature. After 1 hour heating under reflux, the excess of acrylonitrile is removed in vacuo. The residue is extracted with 3-350 ml portions of diethyl ether, the combined diethyl ether extracts are treated with 3.0 g of Darco and 1.0 g of Hyflo, filtered, the filtrate is dried, and concentrated to give 31.6 g of 3-chloro-5,l l-dihydrodibenz[b,e][1,4]oxazepine-5- propionitri1e,b.p. about 200-210 (0.2 min.).

The 3-ch1oro-5,1 1-dihydrodibenz[b,e][ 1,4]oxazepine-5- propionitrile, 71.10 g, is dissolved in 1,200 ml of dry dioxane and to this 800 m1 of 30 percent methanolic hydrogen chloride is added. The solution is stirred for 72 hours, 30 ml of H 0 is added, the mixture is stirred for 0.5 hour, concentrated in vacuo to 400 ml, filtered, and the filtrate concentrated to dryness in vacuo. The residue solidifies on keeping to yield 3- chloro-S ,l l-dihydrodibenz[b,e][ l,4]-oxazepine-5-propionic acid, methyl ester.

The 3-chloro-5,l l-dihydrodibenz[b,e 1,4]oxazepine-5- propionic acid, methyl ester, 25.4 g, is dissolved in 2200 ml of MeOH and to this 5.6 g of KOl-l dissolved in 300 ml of H 0 is added. The solution is refluxed for 4 hours, and then is concentrated in vacuo. The residue is taken up in 600 ml of H 0, the solution is cooled, and then acidified with 2 percent aqueous HCl. The solid is filtered and dissolved in 600 ml of C ll This solution is treated with Darco and then extracted with 600 ml of 2 percent aqueous NaOH solution. The extracts are treated with Darco and l-lyflo, filtered and the filtrate is acidified with 2 percent aqueous HCl. The solid is filtered and recrystallized from C I-l to yield 3-chloro-5,l ldihydrodibenz[b,e][l,4]oxazepine-5-propionic acid (m.p. l38l40).

B. l l-Chloro-l,2-dihydro-3H,8H-quino[1,8-a,b][4,1]- benzoxazepin-3-one 3.7 g of 3-chloro-5,l l-dihydro[b,e][1,4]oxazepine-5- propionic acid is dissolved in 20 ml of warm benzene and the resulting colorless solution is allowed to come to 30, and to this, 1.9 ml (2.8 g) of (CF CO) O is added dropwise. The reaction mixture is slowly heated to reflux, the reflux is maintained for 5 minutes, and the mixture is poured into 250 ml of cold water. To this, 150 ml of benzene is added, and stirred for a few minutes. The benzene layer is separated, washed, dried, filtered, and concentrated to dryness. The residue is recrystallized first from 2-propanol and then from cyclohexane to give 2.3 g of product, mp l42 -144.

EXAMPLE 4 EXAMPLE 5 1,2-Dihydro-l 1-(trifluoromethyl)-3l-l,7l-l-quino[8,l-c,d][ 1,5 ]-benzoxazepin-3-one A. 5,1 1-Dihydro-7-(trifluoromethyl)dibenz[b,e][ l ,4]-oxazepine-5-propionic acid To 50.0 g of 5,1 1-dihydro-7-(trifluoromethyl)dibenz-[ b,e][1,4]oxazepine in 60 ml of redistilled acrylonitrile is added in 5 minutes 0.80 ml of Triton B. Subsequently, the mixture is heated for one hour under reflux and the product isolated by extraction with benzene to give 5,11-dihydro-7- (trifluoromethyl)dibenz[b,e][ 1,4]oxazepine-S-propionitrile, m.p. about 161-163".

7-(Trifluoromethyl)-5,1 l-dihydrodibenz[b,e][ l ,4]-oxazepine-S-propionitrile, 15.0 g, is dissolved in 240 ml of dry dioxane and to this 140 m1 of 30 percent methanolic hydrogen chloride is added. The solution is stirred for 36 hours, 6 ml of B 0 is added, stirred 0.5 hour, and then concentrated in vacuo. to ml. The solid is filtered, and the filtrate is concentrated to dryness in vacuo. The residual liquid is taken up in 200 ml of diethyl ether, treated with Darco and l-lyflo, the diethyl ether solution is concentrated and the residue distilled in vacuo to give 5,1l-dihydro-7-(trifluoromethyl)dibenz[ b,e][ 1,4]-oxazepine--propionic acid, methyl ester, b.p. about 166-168 )0.08 mm.), m.p. about 70.071.5.

7-(Trifluoromethyl)-5 ,1 l-dihydrodibenz[b,e][ 1,4]oxazepine-S-propionic acid, methyl ester, 3.15 g, is dissolved in 315 ml of methanol and to this 0.5 g of potassium hydroxide dissolved in 25 ml of water is added. The mixture is refluxed for 2.5 hours and then concentrated in vacuo. The residue is taken up in 250 ml of water and this solution is acidified with 2 percent aqueous HCl to give 5,1 l-dihydro-7- (trifluoromethyl)dibenz[b,e][ 1,4]oxazepine5-propionic acid, m.p. about 9496. B. 1,2-Dihydro-1 l-(trifluoromethyl)-3H,71-l-quino[8, 1 -c,d]- 1,5 ]-benzoxazepin-3-one A solution of 6.86 g of 5,11-dihydro-7-(trifiuoromethyl) dibenz[b,e][ l,4]oxazepine-5-propionic acid in 50 ml of benzene is cooled to 5-l0. To this is added dropwise with stirring a solution of 4.6 g of PCI,, in 25 ml of benzene over a period of 15 minutes. The solution is stirred at 25 for 40 minutes and then at 40-50 for another 20 minutes. The reaction mixture is then heated at 55 for minutes, cooled to 10 and to this is added dropwise with stirring a solution of 12.0 g anhydrous SnCl, in 20 ml of benzene. After stirring 20 minutes at 10 and 20 minutes at room temperature, 100 ml of ether are added, followed by 10 ml of concentrated hydrochloric acid, and then 100 ml of water. After stirring vigorously for 10 minutes, the organic phase is separated, and the aqueous phase is extracted with 100 ml of ether. The combined organic extracts are washed, dried, filtered, and concentrated to dryness to give 6.9 g of residue; this is crystallized from 2-propano1 to give 4.3 g ofproduct, mp l40-142.

EXAMPLE 6 1,2-Dihydro-l 1-(trifluoromethyl)-3l-l,7l-l-quino[8,l-cd][ 1,5 l-benzoxazepin-3-one To a solution of 64.0 g of 5,1l-dihydro-7- (trifluoromethyl)dibenz[b,e][ l,4]oxazepine-5-propionic acid in 300 ml of anhydrous benzene, is added dropwise 28.2 ml of (CF;,CO) O while stirring. The reaction mixture is slowly heated to reflux temperature and the reflux is maintained for minutes. The solution is then poured into 2,600 ml of cold water and to this 600 ml of benzene is added while stirring. The benzene layer is separated and the aqueous phase is extracted once with 200 ml of benzene. The combined benzene extracts are washed, dried, and filtered. The solvent is removed under reduced pressure to give 62.0 g of yellow solid, which is crystallized twice from 2-propanol to give 50.5 g of a bright yellow crystalline product, mp l42--143.5. A mixture mp with the ketone obtained in Example 5 is 142-l43.5.

EXAMPLE 7 1,2-Dihydro-l 1-(trifluoromethyl)-3H,7H-quino[8,1-c,d][ 1,5 ]-benzoxazepin-3-one,oxime A solution of 28.0 g of the ketone from Example 5, and 13.6 g of hydroxylamine hydrochloride in 600 m1 of warm 70 percent ethanol is refluxed for 4 hours, and kept at room temperature to give a pale yellow crystalline solid. This is filtered and recrystallized from 70 percent ethanol to give 21.0 g of the product, mp 198-200 (dec.).

EXAMPLE 8 l 1-Chloro-l,2-dihydro-3l-l,7l-l-quino[8,1-c,d][ 1,5 ]benzoxazepin-3-one and 4-chloro-l,2-dihydro-3H,8H-quino[1,8- a,b] [4,1 ]-benzoxazepin-3-one A suspension of 17.4 g of 7-chloro-5,l l-dihydrodibenz-[ b,e][ 1 ,4]oxazepine in 35 ml of acrylonitrile is cooled to 0-5. To this is added with efficient stirring and cooling 0.2 ml of Triton B. The suspension becomes homogeneous and a red solution results with the rise of temperature to 10. The reaction mixture is allowed to come to room temperature and then refluxed for one hour with stirring. The excess of acrylonitrile is removed by known means, water is added, and the solid is filtered. The solid is dried, powdered, and extracted with five 400 ml portions of diethyl ether. The diethyl ether extracts are dried and concentrated to a volume of 250 ml. The white crystalline compound is filtered. The filtrate is again concentrated and the resulting solid is filtered. The yield of the combined desired products (ie 7-ch1oro-5,l 1-dihydrodibenz[ b,e]-[1,4]oxazepine-S-propionitrile) is 21.5 g, m.p. about l31l32.

The 7-chloro-5,1 1-dihydrodibenz[b,e][ 1,4]oxazepine-5- propionitrile, 71.10 g, is dissolved in 1,200 ml of dry dioxane and to this 800 ml of 30 percent methanolic hydrogen chloride is added. The solution is stirred for 72 hours, 30 ml of 11 0 is added, the mixture is stirred for 0.5 hour, concentrated in vacuo to 400 ml, filtered, and the filtrate concentrated to dryness in vacuo. The residue solidifies on keeping to yield 7 chloro-5,l 1-dihydrodibenz[b,e][ l,4]-oxazepine-5-propionic acid, methyl ester 67.5 g, m.p. about 7072.

The 7-chloro-5,1 l-dihydrodibenz[b,e][ l,4]oxazepine-5- propionic acid, methyl ester, 25.4 g, is dissolved in 2200 ml of MeOH and to this 5.6 g of KOl-l dissolved in 300 m1 of H 0 is added. The solution is refluxed for 4 hours, and then is concentrated in vacuo. The residue is taken up in 600 ml of H 0, the solution is cooled, and then acidified with 2 percent aqueous l-lCl. The solid is filtered and dissolved in 600 ml of C 11 This solution is treated with Darco and then extracted with 600 ml of 2 percent aqueous NaOH solution. The extracts are treated with Darco and Hyflo, filtered and the filtrate is acidified with 2 percent aqueous HCl. The solid is filtered and recrystallized from C ll The yield of 7-ch1oro-5,l 1- dihydrodibenz[b,e][1,4]oxazepine-5-propionic acid is 23.0 g m.p. about l55.0-156.5

A solution of 7.35 g of 7-chloro-5,l l-dihydrodibenz-[ b,e][ 1,4]oxazepine-5-propionic acid in 40 ml of warm benzene is slowly cooled to 35 and while stirring 3.8 ml of (CF CO) O is added dropwise. The reaction mixture is heated to reflux and the reflux is maintained for 5 minutes. To this 50 ml of benzene is added and the solution is poured into cold water. The yellow benzene layer is separated and the aqueous phase is extracted with 50 ml of benzene. The combined benzene extracts are washed, dried, and concentrated to dryness under reduced pressure. The residue solidifies to an intense yellow material, which weighs 7.0 g, mp 1 l0120. This solid is dissolved in 325 ml of a refluxing mixture of 2- propanol and cyclohexane (2:3), and kept at room temperature for two days, when two different kinds of crystals form. These are filtered and the intense yellow transparent rhombic crystals (compound A) are separated manually from the darker yellow flat needles (compound 8). Compound A melts at -l42 and weighs 1.3 g while compound B melts at 137-143 and weighs 3.4 g.

Compound A, 1.3 g is dissolved in 75 ml of a refluxing mixture of 2-propanol and cyclohexane 1:4), filtered, and kept at room temperature. This gives 1.1 g of intense yellow transparent needles mp 140-142.5. This compound is shown to be 1 l-chloro-1,2-dihydro-3H, 7l-l-quino[8,l-c,d][1,5]benzoxazepine-3-one.

Compound B is dissolved in 225 ml ofa refluxing mixture of 2-propanol and cyclohexane (1:4), filtered, and kept at room temperature to give 2.7 g of darker yellow non-transparent long needles, mp l41.5-144. This compound is shown to be 4-chloro-l ,2-dihydro-3l-l, 8H[1,8-a,b][4,1]benzoxazepin-3- one.

A mixture mp of Compound A and Compound B is l l512 2.

EXAMPLE 9 l l-Chloro-l,2-dihydro-3H,7H-quino[8,1-c,d][1,5]benzoxJ azepin-3-one,oxime A mixture of 360 mg of 1 l-chloro-l,2-dihydro-3l-l, 7H- quino[8,1-c,d][1,5]benzoxazepine-3-one from Example 8, and mg of hydroxylamine hydrochloride is dissolved in 20 ml of warm 70 percent ethanol and refluxed for 3 hours. The

reaction mixture is concentrated to 15 ml and allowed to cool. The resulting pale yellow needles are filtered and recrystallized from 70 percent ethanol to give 285 mg of product, mp 224226 (dec.).

EXAMPLE l 4-Chloro-l ,2-dihydro-3H,8H-quino[ l ,8-a,b][4,1 ]benzoxazepin-3-one,oxime A mixture of 1.3 g of 4-chloro-l,2-dihydro-3H,8H-quin- 0[ 1,8-a,b][4,1lbenzoxazepin-B-one from Example 8, and 0.63 g of hydroxylamine hydrochloride in 140 ml of warm 70 percent ethanol is refluxed for three hours. The reaction mixture is allowed to cool. The resulting pale yellow needles are filtered and recrystallized from 80 percent ethanol to give 1.1 g of product, mp 252-254 (dec.).

EXAMPLE 1 l To a solution of 3.35 g of l,2-dihydrol l-(trifluoromethyl)3 H,7H-quino[8,1-c,d][1,5]benzthiazepin-3-one in 40 ml of CHCl is added 1.8 g of m-chloroperbenzoic acid, and the aqueous Na CO solution, followed by water, dried, and filtered. Removal of solvent gives 3.4 g of residue, which is crystallized from cyclohexane to give 1.8 g of product, mp 155-l57.

EXAMPLE 12 EXAMPLES 13 to 36 Employing the procedure described in Example 1, but substituting the starting material shown in the left hand column of Table 1 below, the product shown in the right hand column is mixture refluxed for 7 hours, cooled, and washed with 5%' obtained.

TABLE 1 Example No. Starting material Product 13 s-cH; s-CH2 m C) C) m O o N 0 ca N HrCHzCOOH K)IO 14 S0-CH1 so-on,

F3C- O O OCH3 F O OCH3 CH N CH CH N JlHzCHaCOOH kJ 15 SOz-CHz SOz-CHz C) O O N CH CH CH L rimomooon V 16 S-CH: SCH2 H C CH, H C 41H,

\NO2S 0 O NO2S 0 H3O CH N CH H3O CH N HzCHzC OOH K20 CH 17 S0435, ([3113 SOr-CH: 3

C H CzHt 2 Nms- 0 O CH; N01S- O N 0 CH N C1H5 C CH 2H5 H2CH2COOH k}o Table l-Continued Product Starting material Example No.

H2CH2C OOH N CH (Lmomooofi S-CHz Table l-Continued Example No. Starting material Product 33 /s-0 Y S0, C Y

on \CH C dmomcoon 34 s-cm s-cHI 35 so-cHi so-on,

C7H5O- /CN C11I50 0 -CN on N CH N CH HzCHzCOOH as s010H= $014311,

EXAMPLES 37 to 62 and Z is O. The corresponding oximes of the compounds of Examples A compound in accordance with Claim 1 wherein A is O l l to 36 can be prepared by reacting the compounds of Examand Z is ples 1 l to 36 with hydroxylamine hydrochloride in ac- 6. A compound in 8CCOl'd8I'lC6 with claim 1 having the f0!- cordance with the procedure of Example 2. "11

EXAMPLES 63 to 84 Employing the procedure of Example 3, using the starting material of Examples 13 to 36 the product shown in the right hand column of Table I is obtained. 0

Furthermore, in Examples 3 and 63 to 84, the trifluoroacetic anhydride can be replaced with polyphosphoric acid/or phosphorus pentoxide to form the products of Ex- N 'i) amples 63 to 84.

What is claimed is: 1. A compound of the structure Zzb b l ll wherein X and Y are the same or different and are selected 7, A compound i a ordan e with claim 1 having the forfrom the group consisting of lower alkyl, lower alkylmercapto, l lower alkoxy, halogen, trifluoromethyl, cyano or di-lower alkylsulfamoyl, A is selected from the group consisting of O, S, 0CH2 S0 or S0 2 is O or =N-OH, n is 0,1, or 2 and n is 0, l or 2;

or salts thereof. 2. A compound in accordance with claim 1 wherein A is O. CH 3. A compound in accordance with claim 1 wherein A is S. I 4. A compound in accordance with claim 1 wherein A is O HON" 25 26 8. A compound in accordance with claim I having the for- 12, A m nd i a ordan e with claim 1 comprising a mula I mixture of compounds having the formulas OCH: an 0-C1I l0 0 9. A compound in accordance with claim 1 having the formula v 0 0H mu li- A compound In accordance with claim 1 having the forl5 f OCH: \N/ CH H0N= I I v 10. A compound in accordance with claim 1 having the for- N mula HO N -OCH2 I CF 0 c\ I 14. A compound in accordance with claim 1 having the for- 1 I mula V O-CHz l l. A compound in accordance with claim 1 having the formula LO O-GH; 01-

- NOH CF v cfi I NOH CERTIFICATE OF CORRECTION Patent No. 2 Dated July ll, 1972 Inventor(s) Harry Louis Yale; Ramesh Petiqara It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

"- "M 1 Column 2, line 1, "other than in the starting" should read -other than 7 in the starting-. Column 2, line 69 "at the 4-position" should read --at the 11' -position--.

Column 6, structure 30: l

should read Column 1?, example no. 17:

0- v 5 --CH ould 2 5 \N S 0 read O 2 C c C 1 4 2 5 I CH CH COOH CH CH COOH T IIEITEI) STATES PATENT ()FFICE 69 CERTIFICATE OF CORRECTION 2 Patent No- 3,676,445 I Dated July 11, 1972 Inventor) Harry Louis Yale; Ramesh Petigara It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 18, structure l7 32 3 UIHTED STATES PATENT OFFER fiERTIFICATE 0F CGRRECTIGN G94 v e Page 3 Patent; No. 3 7 ,445 Dated July 11, 1972 lnventofl Harry Louis Yale; Ramesh Petigara It is certified that error appears in the ab I ove-identified and that said Letters Patent are hereby corrected as shown belcm Column 23, example no. 33:

O-CH O 0 should read CH CH COOH CH CH COOH Claim 1 after the structures delete I arid J II.

Signed and sealed this 23rd day of January 1973.

SEAL) Attest:

ROBERT GOTTSCHALK Commissioner of Patents EDWARD M..FLETCHER,JR. Attesting Officer 

2. A compound in accordance with claim 1 wherein A is O.
 3. A compound in accordance with claim 1 wherein A is S.
 4. A compound in accordance with claim 1 wherein A is O and Z is O.
 5. A compound in accordance with claim 1 wherein A is O and Z is N-OH.
 6. A compound in accordance with claim 1 having the formula
 7. A compound in accordance with claim 1 having the formula
 8. A compound in accordance with claim 1 having the formula
 9. A compound in accordance with claim 1 having the formula
 10. A compound in accordance with claim 1 having the formula
 11. A compound in accordance with claim 1 having the formula
 12. A compound in accordance with claim 1 comprising a mixture of compounds having the formulas
 13. A compound in accordance with claim 1 having the formula
 14. A compound in accordance with claim 1 having the formula 